These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 25667169)

  • 41. Development of new antibiotics: taking off finally?
    Bettiol E; Harbarth S
    Swiss Med Wkly; 2015; 145():w14167. PubMed ID: 26230280
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria.
    Avery LM; Nicolau DP
    Expert Opin Investig Drugs; 2018 Apr; 27(4):325-338. PubMed ID: 29611447
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
    Eljaaly K; Alharbi A; Alshehri S; Ortwine JK; Pogue JM
    Drugs; 2019 Feb; 79(3):243-269. PubMed ID: 30723876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New therapeutic options for respiratory tract infections.
    Bassetti M; Righi E; Carnelutti A
    Curr Opin Infect Dis; 2016 Apr; 29(2):178-86. PubMed ID: 26871402
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ESKAPEing the labyrinth of antibacterial discovery.
    Tommasi R; Brown DG; Walkup GK; Manchester JI; Miller AA
    Nat Rev Drug Discov; 2015 Aug; 14(8):529-42. PubMed ID: 26139286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?
    Page MG; Bush K
    Curr Opin Pharmacol; 2014 Oct; 18():91-7. PubMed ID: 25277839
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potent Antibiotics Active against Multidrug-Resistant Gram-Negative Bacteria.
    Otsuka Y
    Chem Pharm Bull (Tokyo); 2020; 68(3):182-190. PubMed ID: 32115524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009].
    Hamouche E; Sarkis DK
    Pathol Biol (Paris); 2012 Jun; 60(3):e15-20. PubMed ID: 21719212
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Variation in definitions and isolation procedures for multidrug-resistant Gram-negative bacteria: a survey of the Society for Healthcare Epidemiology of America Research Network.
    Drees M; Pineles L; Harris AD; Morgan DJ
    Infect Control Hosp Epidemiol; 2014 Apr; 35(4):362-6. PubMed ID: 24602940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fight Against Antimicrobial Resistance: We Always Need New Antibacterials but for Right Bacteria.
    Duval RE; Grare M; Demoré B
    Molecules; 2019 Aug; 24(17):. PubMed ID: 31470632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria.
    Kidd JM; Kuti JL; Nicolau DP
    Expert Opin Pharmacother; 2018 Mar; 19(4):397-408. PubMed ID: 29411661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G; Rossolini GM
    Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii.
    Chopra S; Torres-Ortiz M; Hokama L; Madrid P; Tanga M; Mortelmans K; Kodukula K; Galande AK
    J Antimicrob Chemother; 2010 Dec; 65(12):2598-601. PubMed ID: 20861141
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
    Falagas ME; Mavroudis AD; Vardakas KZ
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [New antibacterial agents on the market and in the pipeline].
    Kern WV
    Internist (Berl); 2015 Nov; 56(11):1255-63. PubMed ID: 26475603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validated Preclinical Mouse Model for Therapeutic Testing against Multidrug-Resistant Pseudomonas aeruginosa Strains.
    Warawa JM; Duan X; Anderson CD; Sotsky JB; Cramer DE; Pfeffer TL; Guo H; Adcock S; Lepak AJ; Andes DR; Slone SA; Stromberg AJ; Gabbard JD; Severson WE; Lawrenz MB
    Microbiol Spectr; 2022 Oct; 10(5):e0269322. PubMed ID: 36094219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.